News
Media
Conferences
Events
Partners
Publications
Resources
Biomarker Consortium
Subscribe

Apar Ganti, MD, University of Nebraska Medical Center

Articles by Apar Ganti, MD, University of Nebraska Medical Center

Q & A and Final Thoughts

ByVivek Subbiah, MD, MD Anderson Cancer Center,Anne Chiang, MD, PhD, Yale School of Medicine Smilow Cancer Hospital,Apar Ganti, MD, University of Nebraska Medical Center

August 20th 2020

Unmet Needs and Challenges in Treating R/R SCLC

ByVivek Subbiah, MD, MD Anderson Cancer Center,Anne Chiang, MD, PhD, Yale School of Medicine Smilow Cancer Hospital,Apar Ganti, MD, University of Nebraska Medical Center

August 20th 2020

Role of Newer Agents in the Treatment & Patient Selection

ByVivek Subbiah, MD, MD Anderson Cancer Center,Anne Chiang, MD, PhD, Yale School of Medicine Smilow Cancer Hospital,Apar Ganti, MD, University of Nebraska Medical Center

August 20th 2020

Data on FDA Approved Therapy for Relapsed/Refractory SCLC

ByVivek Subbiah, MD, MD Anderson Cancer Center,Anne Chiang, MD, PhD, Yale School of Medicine Smilow Cancer Hospital,Apar Ganti, MD, University of Nebraska Medical Center

August 20th 2020

Use of I/O Regimen in Relapsed/Refractory SCLC

ByVivek Subbiah, MD, MD Anderson Cancer Center,Anne Chiang, MD, PhD, Yale School of Medicine Smilow Cancer Hospital,Apar Ganti, MD, University of Nebraska Medical Center

August 20th 2020

Advice on Toxicity Management for SCLC Therapy

ByVivek Subbiah, MD, MD Anderson Cancer Center,Anne Chiang, MD, PhD, Yale School of Medicine Smilow Cancer Hospital,Apar Ganti, MD, University of Nebraska Medical Center

August 20th 2020

Personal Approach in Treatment Compared to Clinical Trials

ByVivek Subbiah, MD, MD Anderson Cancer Center,Anne Chiang, MD, PhD, Yale School of Medicine Smilow Cancer Hospital,Apar Ganti, MD, University of Nebraska Medical Center

August 20th 2020

Recent Progress in the Treatment of SCLC

ByVivek Subbiah, MD, MD Anderson Cancer Center,Anne Chiang, MD, PhD, Yale School of Medicine Smilow Cancer Hospital,Apar Ganti, MD, University of Nebraska Medical Center

August 20th 2020

Introduction and Identifying Predictive Biomarkers

ByVivek Subbiah, MD, MD Anderson Cancer Center,Anne Chiang, MD, PhD, Yale School of Medicine Smilow Cancer Hospital,Apar Ganti, MD, University of Nebraska Medical Center

August 20th 2020

Latest Updated Articles

Role of Newer Agents in the Treatment & Patient Selection
August 20th 2020
Advice on Toxicity Management for SCLC Therapy
August 20th 2020
$Data on FDA Approved Therapy for Relapsed/Refractory SCLC$
Data on FDA Approved Therapy for Relapsed/Refractory SCLC
August 20th 2020
Q & A and Final Thoughts
August 20th 2020
Recent Progress in the Treatment of SCLC
August 20th 2020
$Use of I/O Regimen in Relapsed/Refractory SCLC$
Use of I/O Regimen in Relapsed/Refractory SCLC
August 20th 2020

Trending on OncLive

FDA Approves Subcutaneous Isatuximab Delivered Via On-Body Delivery System for Multiple Myeloma

FDA Approves Pembrolizumab Plus Enfortumab Vedotin in MIBC

Risvutatug Rezetecan Shows OS Benefit Over Topotecan in Relapsed SCLC

OncLive Weekly News Quiz (7/10/2026): Test Your Knowledge on Key Updates in Myeloma, MIBC, and More

FDA Approves Pegfilgrastim Biosimilar for Non-Myeloid Malignancies